ENTA - Company ID 0001177648
The table below shows ENANTA PHARMACEUTICALS INC's income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $65.32M | $67.64M | $79.20M | $86.16M | $97.07M | $122.47M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $106.74M | $131.48M | $163.52M | $164.52M | $174.11M | $136.76M |
| SG&A |
ENANTA PHARMACEUTICALS INC reported annual revenue of $65.32M for fiscal year 2025. That is down 3.4% from $67.64M in fiscal 2024. Over the 10 fiscal years shown, annual revenue declined from $88.27M (FY 2016) to $65.32M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $43.93M |
| $57.85M |
| $52.89M |
| $45.48M |
| $32.54M |
| $27.36M |
| Operating income | -$85.35M | -$121.69M | -$137.21M | -$123.84M | -$109.57M | -$41.64M |
| Income tax | -$1.66M | -$1.74M | $2.82M | -$433.00K | -$28.58M | $1.15M |
| Net income | -$81.89M | -$116.05M | -$133.82M | -$121.75M | -$79.00M | -$36.17M |
| EPS (diluted) | -$3.84 | -$5.48 | -$6.38 | -$5.91 | -$3.92 | -$1.81 |